Cargando…

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still rapidly spreading worldwide. Many drugs and vaccines have been approved for clinical use show efficacy in the treatment and prevention of SARS-CoV-2 infections. However, the emergence of SARS-CoV-2 variants of concern (VOCs), such...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xinghai, Zhang, Huajun, Li, Tingting, Chen, Shaohong, Luo, Feiyang, Zhou, Junhui, Zheng, Peiyi, Song, Shuyi, Wu, Yan, Jin, Tengchuan, Tang, Ni, Jin, Aishun, Yang, Chengyong, Cheng, Guofeng, Gong, Rui, Chiu, Sandra, Huang, Ailong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424799/ https://www.ncbi.nlm.nih.gov/pubmed/36042204 http://dx.doi.org/10.1038/s41392-022-01135-3

Ejemplares similares

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
por: Ma, Huan, et al.
Publicado: (2022)

A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
por: Ma, Huan, et al.
Publicado: (2022)

Structures of Omicron spike complexes and implications for neutralizing antibody development
por: Guo, Hangtian, et al.
Publicado: (2022)

Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates
por: Wu, Yi, et al.
Publicado: (2022)

A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding
por: Long, Yingyi, et al.
Publicado: (2021)

Delta-Omicron recombinant escapes therapeutic antibody neutralization
por: Duerr, Ralf, et al.
Publicado: (2023)

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
por: Li, Tingting, et al.
Publicado: (2021)

Harringtonine: A more effective antagonist for Omicron variant
por: Hu, Shiling, et al.
Publicado: (2023)

Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters
por: Zhang, Xinghai, et al.
Publicado: (2022)

Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants
por: Cacciottolo, Mafalda, et al.
Publicado: (2023)

Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
por: Lu, Jia, et al.
Publicado: (2022)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

SARS-CoV-2 spike protein S1 subunit induces potent neutralizing responses in mice and is effective against Delta and Omicron variants
por: Mamedov, Tarlan, et al.
Publicado: (2023)

Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant
por: Khan, Khadija, et al.
Publicado: (2022)

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
por: Kombe Kombe, Arnaud John, et al.
Publicado: (2021)

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants
por: Servellita, Venice, et al.
Publicado: (2022)

Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence
por: Hastie, Kathryn M., et al.
Publicado: (2023)

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine
por: Li, Wanting, et al.
Publicado: (2023)

Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection
por: Mu, Song, et al.
Publicado: (2022)

Nanoparticle-based multivalent human antibodies offer potent and broad neutralization against Omicron sublineages
por: Wang, Yizhen, et al.
Publicado: (2023)

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
por: Walls, Alexandra C., et al.
Publicado: (2021)

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
por: Chen, Zhaochun, et al.
Publicado: (2022)

Neutralization Effect of Sera against Delta and Omicron in Patients Recovering from COVID-19 and Inactivated Vaccine Recipients
por: Zhu, Yajuan, et al.
Publicado: (2023)

Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection
por: Linderman, Susanne L., et al.
Publicado: (2022)

Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron’s outbreak
por: Ren, Zhenxiao, et al.
Publicado: (2022)

Will New Variants Emerge after Delta and Omicron?
por: Yang, Zhen, et al.
Publicado: (2022)

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
por: Wang, Yingdan, et al.
Publicado: (2022)

Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA
por: Zeng, Weihong, et al.
Publicado: (2021)

Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection
por: Pidal, Paola, et al.
Publicado: (2022)

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
por: Lee, I-Jung, et al.
Publicado: (2022)

Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants
por: Du, Wangqi, et al.
Publicado: (2022)

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern
por: Schultz, Bárbara M., et al.
Publicado: (2022)

Delta or Omicron BA.1/2‐neutralizing antibody levels and T‐cell reactivity after triple‐vaccination or infection
por: Rose, Ruben, et al.
Publicado: (2022)

A potent and broad‐spectrum neutralizing nanobody for SARS‐CoV‐2 viruses, including all major Omicron strains
por: Yao, Hebang, et al.
Publicado: (2023)

A SARS-CoV-2 antibody retains potent neutralization against Omicron by targeting conserved RBM residues
por: Yi, Chunyan, et al.
Publicado: (2022)

Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination
por: Chi, Xiangyang, et al.
Publicado: (2022)

Neutralization susceptibility of Omicron lineages
por: Minton, Kirsty
Publicado: (2022)

Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern
por: Kondo, Taishi, et al.
Publicado: (2022)

Broad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection
por: Seow, Jeffrey, et al.
Publicado: (2023)

Distinct Clinical and Laboratory Features of COVID-19 in Children During the Pre-Delta, Delta and Omicron Wave
por: Han, Mi Seon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_52oisunvuonoqiv16ugv87539u